CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00525902
NCT00525902Phase 2Completed
CompareCT.gov

An Open-label, Multicenter, Phase II Trial of Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

Oregon Health and Science University·interventional·Posted Sep 6, 2007·Updated Apr 11, 2012

In Brief

A Phase 2 clinical trial evaluating Adalimumab for Uveitis. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesUnited States
CollaboratorsUniversity of Illinois at Chicago, The Cleveland Clinic

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 6, 2007
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.8 years ago

Interventions

Adalimumabdrug

40 mg delivered every 2 weeks by subcutaneous injection